BiCNU

(Carmustine)

ApprovedSmall molecule

Carmustine is a chemotherapy drug used to treat certain cancers including brain tumors, lymphomas, and multiple myeloma by damaging cancer cell DNA and stopping them from growing.[2] BiCNU is currently approved and in use across 46 indications[4].[1]

BiCNU is one of 930 small molecule programs targeting Glioma. It is currently in Approved.

Indications

165

Total Trials

Active Trials

929

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

GliomaActive, not recruiting

EpendymomaActive, not recruiting

HIV InfectionActive, not recruiting

AstrocytomaActive, not recruiting

Non-Hodgkins LymphomaActive, not recruiting

ParagangliomaApproved

Central Nervous System CancerActive, not recruiting

Unspecified Peripheral T-Cell LymphomaApproved

T-Cell Non-Hodgkin LymphomaActive, not recruiting

Anaplastic Large Cell LymphomaActive, not recruiting

GliomaPhase 3

Active, not recruiting

EpendymomaApproved

Active, not recruiting

HIV InfectionPhase 1

Active, not recruiting

AstrocytomaApproved

Active, not recruiting

Non-Hodgkins LymphomaApproved

Active, not recruiting

ParagangliomaApproved

Approved

Central Nervous System CancerPhase 2

Active, not recruiting

Unspecified Peripheral T-Cell LymphomaApproved

Approved

T-Cell Non-Hodgkin LymphomaPhase 1

Active, not recruiting

Anaplastic Large Cell LymphomaPreclinical

Active, not recruiting

Showing 10 of 46 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

BiCNU

MMelissa K Accordino

Approved

4 2

Tecentriq

Roche

Preclinical

36 3

Tykerb

GSK

Preclinical

80 4

Nolvadex

SSan Diego Pacific Oncology & Hematology Associates

Preclinical

78 5

Adriamycin

GGynecologic Oncology Group

Preclinical

87 6

Avastin

Prolia

14 8

DATROWAY

Daiichi Sankyo

Preclinical

4 9

Blenoxane

Bristol-Myers Squibb

Preclinical

1 10

Voltaren

Novartis

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Recruiting

Refractory Solid Tumors

NCT05521984

Phase 2Recruiting

Stem Cell

NCT05052957

Phase 3Active, not recruiting

Diffuse Large B-Cell Lymphoma Activated B-Cell Type

NCT02443077

Q2 2027

Phase 2Active, not recruiting

Lymphoma

NCT01511562

Phase 2Active, not recruiting

Uveal Melanoma

NCT04728633

Q3 2027

Phase 2Recruiting

Stem Cell Transplant

NCT06377540

Clinical

Trials by Indication[1]

Lymphoma49 trials

Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Hodgkin's or Non-Hodgkin's Lymphoma

Completed·CChildren's Oncology Group·Phase 2·NCT00002941·69 enrolled

Tazemetostat Plus CHOP in 1L T-cell Lymphoma

Suspended·—·Phase 2·NCT06692452·24 enrolled

Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma

Completed·MMontefiore Medical Center·Phase 2·NCT00002461·35 enrolled

Show 46 more trials

Autologous Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma

Completed·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT00345865·473 enrolled

Chemotherapy and Whole-Brain Radiation Therapy in Treating Patients With Primary Central Nervous System Non- Hodgkin's Lymphoma

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00002676·36 enrolled

Stem Cell Transplantation With or Without Rituximab in Treating Patients With Relapsed or Progressive B-Cell Diffuse Large Cell Lymphoma

Completed·EEastern Cooperative Oncology Group·Phase 3·NCT00052923·427 enrolled

High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT01840566·17 enrolled

Immunotherapy Using Cyclosporine, Interferon Gamma, and Interleukin-2 After High-Dose Myeloablative Chemotherapy With Autologous Stem Cell Transplantation in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma

Completed·CChildren's Oncology Group·Phase 2/3·NCT00070187·24 enrolled

High-Dose Chemotherapy in Treating Patients Undergoing Stem Cell Transplant for Recurrent or Refractory Hodgkin's Lymphoma

Completed·—·N/A·NCT00544570·30 enrolled

Rituximab & Combination Chemotherapy Followed by Transplantation in Relapsed or Refractory Non-Hodgkin's Lymphoma

Completed·UUniversity of Nebraska·Phase 2·NCT00007852·44 enrolled

Combination Chemotherapy and Peripheral Stem Cell Transplant in Treating Patients With Relapsed Hodgkin's Lymphoma

Unknown status·GGerman Hodgkin's Lymphoma Study Group·Phase 3·NCT00025636·220 enrolled

Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT03019640·22 enrolled

Monoclonal Antibody Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplant in Non-Hodgkin's Lymphoma

Completed·UUniversity of Nebraska·Phase 2·NCT00006695·50 enrolled

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Older Patients With Refractory or Relapsed Intermediate-Grade Non-Hodgkin's Lymphoma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00002982

High-Dose Chemotherapy Given Together With Peripheral Blood Stem Cell Transplant in Treating Patients With Intestinal T-Cell Lymphoma

Unknown status·CCancer Research UK·Phase 2·NCT00669812·60 enrolled

Carmustine, Etoposide, Cyclophosphamide, and Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma

Active, not recruiting·—·Phase 1·NCT00641381·25 enrolled

Combination Chemotherapy With or Without Autologous Stem Cell Transplant in Treating Patients With Central Nervous System B-Cell Lymphoma

Active, not recruiting·AAlliance for Clinical Trials in Oncology·Phase 2·NCT01511562·113 enrolled

Carmustine, Etoposide, Cytarabine, Melphalan, and Alemtuzumab Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Unknown status·CCancer Research UK·Phase 2·NCT00908180·47 enrolled

Combination Chemotherapy Followed By Autologous Stem Cell Transplant, and White Blood Cell Infusions in Treating Patients With Non-Hodgkin's Lymphoma

Completed·BBarbara Ann Karmanos Cancer Institute·Phase 1·NCT00244946·15 enrolled

Cyclophosphamide W/or W/Out Rituximab and Peripheral Stem Cell Transplantation in Patients With Recurrent Non-Hodgkin's Lymphoma

Completed·—·Phase 2·NCT00028665·37 enrolled

Radiolabeled Monoclonal Antibody Therapy and High-Dose Chemotherapy Followed By Autologous Peripheral Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Completed·NNorthwestern University·Phase 1·NCT00058292·44 enrolled

Filgrastim and Chemotherapy Followed by Peripheral Stem Cell Transplant in Treating Patients With Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma

Completed·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT00005985·213 enrolled

ChiCGB vs BEAM in High-risk or R/R Lymphomas

Unknown status·SSichuan University·Phase 3·NCT05466318·306 enrolled

Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma

Completed·FFred Hutchinson Cancer Center·Phase 1/2·NCT00005803·76 enrolled

Combination Chemotherapy With or Without Total-Body Irradiation Followed By Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma

Completed·—·Phase 2·NCT00559104·60 enrolled

New Combination of Chemoimmunotherapy for Systemic B-cell Lymphoma With Central Nervous System Involvement

Completed·IInternational Extranodal Lymphoma Study Group (IELSG)·Phase 2·NCT02329080·79 enrolled

Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma

Withdrawn·FFred Hutchinson Cancer Center·N/A·NCT01769911

Gene Therapy-Treated Stem Cells in Treating Patients Undergoing Stem Cell Transplant for Intermediate-Grade or High-Grade AIDS-Related Lymphoma

Completed·—·Phase 1·NCT00569985·5 enrolled

Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00992446·27 enrolled

Chemotherapy and Peripheral Stem Cell Transplant With or Without Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma

Completed·CCommissie Voor Klinisch Toegepast Onderzoek·Phase 3·NCT00012051·340 enrolled

SWOG-9704 Chemoradiotherapy and Peripheral Stem Cell Transplantation Compared With Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma

Completed·SSWOG Cancer Research Network·Phase 3·NCT00004031·397 enrolled

Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma

Recruiting·—·Phase 2·NCT04871607·33 enrolled

Rituximab, Carmustine; Cytarabine, Etoposide, & Melphalan; Stem Cell Transplantation for Non-Hodgkin's Lymphoma

Completed·UUniversity of Nebraska·Phase 2·NCT00080886·68 enrolled

Peripheral Stem Cell Transplantation With Specially Treated Stem Cells in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease

Withdrawn·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT00005998

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma

Completed·EEBMT Solid Tumors Working Party·Phase 3·NCT00005589·460 enrolled

Study of Melphalan HCl for Injection (Propylene Glycol-free), Carmustine, Etoposide, Cytarabine (BEAM Regimen) and Autologous Stem Cell Transplantation for Lymphoma

Completed·WWashington University School of Medicine·Phase 2·NCT01969435·50 enrolled

Gene Therapy and Chemotherapy in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma

Terminated·—·Phase 1·NCT00003567·8 enrolled

Chemotherapy Plus Radiation Therapy in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00003631·118 enrolled

Combination Chemotherapy in Treating Patients With Lymphoma

Completed·MM.D. Anderson Cancer Center·Phase 3·NCT00002835·116 enrolled

Bendamustine Bridge to Autologous or Allogeneic Transplant for Relapsed/Refractory Lymphoma

Completed·WWeill Medical College of Cornell University·Phase 1/2·NCT02059239·34 enrolled

Peripheral Stem Cell Transplantation Plus Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma

Completed·UUniversity of Maryland, Baltimore·Phase 2·NCT00003397·25 enrolled

Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BEAM Followed By ASCT For Relapsed B-Cell Non-Hodgkin Lymphoma

Completed·—·Phase 2·NCT00695409·122 enrolled

Three Different Therapy Regimens in Treating Patients With Previously Untreated Hodgkin Lymphoma

Terminated·FFrench Innovative Leukemia Organisation·Phase 3·NCT00920153·442 enrolled

GM-CSF and Rituximab After Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Follicular Non-Hodgkin Lymphoma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00521014·14 enrolled

S0410 Tandem Stem Cell Transplantation in Treating Patients With Progressive or Recurrent Hodgkin's Lymphoma

Completed·SSWOG Cancer Research Network·Phase 2·NCT00233987·98 enrolled

Lenalidomide Therapy After Chemotherapy & Stem Cell Transplant in Treating Chemotherapy Resistan Non-Hodgkin Lymphoma

Completed·UUniversity of Nebraska·Phase 1/2·NCT01035463·74 enrolled

Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma

Completed·OOhio State University Comprehensive Cancer Center·Phase 1/2·NCT03583424·19 enrolled

Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma

Completed·—·Phase 1·NCT01476839·25 enrolled

CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma

Withdrawn·MM.D. Anderson Cancer Center·Phase 1/2·NCT03579927

Glioblastoma Multiforme10 trials

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00003996·93 enrolled

Computer Planned Radiation Therapy Plus Chemotherapy in Treating Patients With Glioblastoma Multiforme

Completed· Radiation Therapy Oncology Group logo

Radiation Therapy Oncology Group·Phase 1/2·NCT00003417·40 enrolled

Carmustine and O(6)-Benzylguanine in Treating Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme

Withdrawn·—·Phase 2·NCT00046878

Show 7 more trials

NovoTTF-100A With Bevacizumab and Carmustine in Treating Patients With Glioblastoma Multiforme in First Relapse

Withdrawn·UUniversity of California, Davis·Phase 2·NCT02348255

Radiation Therapy Plus Chemotherapy in Treating Patients With Supratentorial Glioblastoma Multiforme

Completed· Radiation Therapy Oncology Group logo

Radiation Therapy Oncology Group·Phase 3·NCT00002545·200 enrolled

S0001 RT and Carmustine With or Without O6BG in Patients With New Glioblastoma Multiforme or Gliosarcoma

Completed·SSWOG Cancer Research Network·Phase 3·NCT00017147·183 enrolled

Study of IV Edotecarin Vs Temozolomide or Carmustine (BCNU) or Lomustine (CCNU) in Patients With Glioblastoma Multiforme

Completed· Pfizer logo

Pfizer·Phase 3·NCT00068952·118 enrolled

Erlotinib Compared With Temozolomide or Carmustine in Treating Patients With Recurrent Glioblastoma Multiforme

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT00086879·110 enrolled

Irinotecan Plus Radiation Therapy Followed By Chemotherapy in Treating Patients With Glioblastoma Multiforme

Completed·AAlliance for Clinical Trials in Oncology·Phase 1/2·NCT00027612·58 enrolled

Radiation Therapy Followed by Carmustine in Treating Patients Who Have Supratentorial Glioblastoma Multiforme

Completed· Radiation Therapy Oncology Group logo

Radiation Therapy Oncology Group·Phase 2·NCT00006386·80 enrolled

Multiple Myeloma10 trials

Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Multiple Myeloma

Completed·UUniversity of Maryland, Baltimore·Phase 2·NCT00003401

Combination Chemotherapy With or Without Cyclophosphamide and Prednisone in Treating Older Patients With Multiple Myeloma

Unknown status·MMedical Research Council·Phase 3·NCT00002653·1,000 enrolled

High-Dose Sequential Therapy and Single Autologous Transplantation for Multiple Myeloma

Completed·SStanford University·Phase 2·NCT00349778·102 enrolled

Show 7 more trials

O6-benzylguanine And Carmustine in Treating Patients With Multiple Myeloma

Completed·—·Phase 2·NCT00004072·17 enrolled

Filgrastim Compared With Sargramostim Plus Chemotherapy, Peripheral Stem Cell Transplantation, and Interferon Alfa in Treating Patients With Multiple Myeloma

Terminated·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT00005987·87 enrolled

A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion

Unknown status·SSwedish Medical Center·Phase 2·NCT03570983·100 enrolled

Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Multiple Myeloma

Completed·UUniversity of Maryland, Baltimore·Phase 2·NCT00003399

Chemotherapy and Peripheral Stem Cell Transplantation Followed By Immunotherapy in Treating Patients With Multiple Myeloma

Completed·UUniversity of Maryland, Baltimore·Phase 1/2·NCT00046852

Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma

Completed·OOHSU Knight Cancer Institute·Phase 1·NCT02504359·11 enrolled

Combination Chemotherapy With or Without High Dose Cyclophosphamide and Recombinant Interferon Alfa-2b in Treating Patients With Previously Untreated Stage I-III Multiple Myeloma

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT00002556·312 enrolled

Malignant Glioma9 trials

Hyperfractionated RT With BCNU Versus Conventional RT With BCNU for Supratentorial Malignant Glioma

Completed· Radiation Therapy Oncology Group logo

Radiation Therapy Oncology Group·Phase 3·NCT03722355·712 enrolled

Efaproxiral Plus Carmustine in Treating Patients With Progressive or Recurrent Malignant Glioma

Completed·NNew Approaches to Brain Tumor Therapy Consortium·Phase 1/2·NCT00005855·48 enrolled

Chemotherapy in Treating Patients With Recurrent Malignant Glioma

Completed·—·Phase 1·NCT00002986·36 enrolled

Show 6 more trials

O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients With Malignant Gliomas

Terminated·FFred Hutchinson Cancer Center·Phase 1/2·NCT00669669·12 enrolled

Irinotecan Plus Carmustine in Treating Patients With Recurrent Primary Malignant Glioma

Completed·—·Phase 1·NCT00002988·36 enrolled

Carmustine in Treating Patients With Recurrent Malignant Glioma

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00004028

Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Recurrent Malignant Glioma

Unknown status·SShandong Lanjin Pharmaceuticals Co.,Ltd·N/A·NCT01637753·212 enrolled

Combination Chemotherapy Following Radiation Therapy in Treating Patients With Malignant Glioma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT00005637

Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Newly Diagnosed Malignant Glioma

Unknown status·SShandong Lanjin Pharmaceuticals Co.,Ltd·Phase 3·NCT01656980·236 enrolled

Glioma7 trials

Surgery, Radiation Therapy, and Chemotherapy With or Without Photodynamic Therapy in Treating Patients With Newly Diagnosed or Recurrent Malignant Supratentorial Gliomas

Unknown status·CColorado Health Foundation·Phase 3·NCT00003788·270 enrolled

Carmustine in Treating Adults With Recurrent Supratentorial Low-Grade Glioma

Completed·—·Phase 2·NCT00003467·68 enrolled

Temozolomide and Carmustine in Treating Patients With Anaplastic Glioma

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT00003176·82 enrolled

Show 4 more trials

Carmustine Wafers Plus Irinotecan in Treating Patients With Recurrent Supratentorial High Grade Gliomas

Completed·—·Phase 1·NCT00003463

Bevacizumab and Carmustine in Treating Patients With Relapsed or Progressive High-Grade Glioma

Completed·UUniversity of California, Davis·Phase 2·NCT00795665·7 enrolled

Carmustine Plus O(6)-Benzylguanine in Treating Patients With Recurrent or Progressive Gliomas of the Brain

Completed·—·Phase 1·NCT00003348·56 enrolled

Carmustine Plus O6-benzylguanine in Treating Patients With Recurrent or Progressive Glioma

Completed·—·Phase 2·NCT00005081

50 more indications

Mantle Cell Lymphoma5 trials

Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00006747·4 enrolled

Efficacy of Upfront and Maintenance Obinutuzumab in Mantle Cell Lymphoma Treated by DHAP and MRD Driven Maintenance

Completed·TThe Lymphoma Academic Research Organisation·Phase 2·NCT02896582·86 enrolled

Donor Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma

Unknown status·CCancer Research UK·Phase 2·NCT00720447·25 enrolled

Show 2 more trials

Chemotherapy Followed by Radiation Therapy and Peripheral Stem Cell Transplant Compared With Chemotherapy Plus Interferon Alfa in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma

Unknown status·GGerman Low Grade Lymphoma Study Group·Phase 3·NCT00016887

Chemotherapy and Rituximab With Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00020943·79 enrolled

Diffuse Large B-Cell Lymphoma5 trials

Rituximab, Cyclophosphamide, and G-CSF Followed By Combination Chemotherapy in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant Followed By Rituximab and GM-CSF for Refractory Diffuse Large B-Cell Lymphoma

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT00242996·44 enrolled

Rituximab in Addition to Chemotherapy With Autologous Stem Cell Transplantation as Treatment Diffuse Large B-Cell Lymphoma

Completed·GGruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie·Phase 2·NCT00556127·94 enrolled

Blinatumomab Consolidation Post Autologous Stem Cell Transplantation in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

Completed·WWashington University School of Medicine·Phase 1·NCT03072771·14 enrolled

Show 2 more trials

CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell Transplant

Recruiting·WWashington University School of Medicine·Phase 2·NCT06687772·36 enrolled

Loncastuximab Tesirine in Combination With Chemotherapy Prior to Stem Cell Transplant for the Treatment of Recurrent or Refractory Diffuse Large B-Cell Lymphoma

Withdrawn·FFred Hutchinson Cancer Center·Phase 1·NCT05228249

Breast Cancer4 trials

Filgrastim Plus Chemotherapy Compared With Filgrastim Alone In Treating Women Undergoing Peripheral Stem Cell Transplantation For Breast Cancer

Completed·MM.D. Anderson Cancer Center·Phase 3·NCT00002836·184 enrolled

Chemotherapy and Peripheral Stem Cell Transplantation Followed by Trastuzumab in Treating Women With Metastatic Breast Cancer

Withdrawn·—·Phase 1/2·NCT00006123

Autologous Hematopoietic Stem Cell Transplantation as Adjuvant Treatment for Triple Negative Breast Cancer Patients

Unknown status·IInstituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran·Phase 2·NCT02670109·20 enrolled

Show 1 more trial

S9623, Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer

Terminated·SSWOG Cancer Research Network·Phase 3·NCT00002772·602 enrolled

Lymphoid Malignancies4 trials

Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid Malignancies

Completed·FFred Hutchinson Cancer Center·Phase 1/2·NCT01921387·20 enrolled

Bortezomib and Chemotherapy in Treating Participants With Lymphoid Malignancies Undergoing Stem Cell Transplant

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00439556·40 enrolled

Rituximab in Addition to Autologous Transplantation With BEAM for Patients With Lymphoid Malignancies

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00472056·93 enrolled

Show 1 more trial

CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT00968760·34 enrolled

Bone Marrow Transplantation4 trials

Chemotherapy and Radiation Therapy Plus Bone Marrow Transplantation in Treating Patients With Aggressive Non-Hodgkin's Lymphoma

Unknown status·SScotland and Newcastle Lymphoma Group·Phase 3·NCT00003815

High-Dose Chemotherapy, Total-Body Irradiation, and Autologous Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Hematologic Cancer or Solid Tumors

Completed·RRoswell Park Cancer Institute·Phase 2·NCT00060255·451 enrolled

High Dose Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Intermediate- or High-Grade Non-Hodgkin's Lymphoma

Unknown status·LLymphoma Trials Office·Phase 3·NCT00003578·500 enrolled

Show 1 more trial

Chemotherapy Plus Bone Marrow Transplantation in Treating Patients With Refractory Non-Hodgkin's Lymphoma, Hodgkin's Disease, or Multiple Myeloma

Completed·BBarbara Ann Karmanos Cancer Institute·Phase 2·NCT00002552·40 enrolled

Stem Cell Transplant4 trials

Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell Malignancies

Terminated·FFred Hutchinson Cancer Center·Phase 1·NCT02483000·3 enrolled

High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors

Completed·RRoswell Park Cancer Institute·N/A·NCT00536601·174 enrolled

Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer

Terminated·OOHSU Knight Cancer Institute·Phase 2·NCT00281879·200 enrolled

Show 1 more trial

MT2022-60: A Phase II Study of Pembrolizumab+ BEAM Conditioning Regimen Before Autologous Stem Cell Transplant (ASCT) Followed by Pembrolizumab Maintenance in Patients of Relapsed or Refractory Classic Hodgkin Lymphoma

Recruiting·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT06377540·28 enrolled

Chronic Lymphocytic Leukemia4 trials

Combination Chemotherapy, Total-Body Irradiation, and Alemtuzumab in Treating Patients Undergoing an Autologous Stem Cell Transplant for Stage I, Stage II, Stage III, or Stage IV Chronic Lymphocytic Leukemia

Completed·GGerman CLL Study Group·Phase 2·NCT00276809·30 enrolled

Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Completed·UUniversity of Maryland, Baltimore·Phase 2·NCT00003402·35 enrolled

Cyclophosphamide and Total Body Irradiation in Treating Patients Who Are Undergoing an Autologous Peripheral Stem Cell Transplant For Chronic Lymphocytic Leukemia

Completed·GGerman CLL Study Group·Phase 2·NCT00275015·169 enrolled

Show 1 more trial

Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT01008462·16 enrolled

Cutaneous T-cell lymphoma2 trials

O6-Benzylguanine and Topical Carmustine in Treating Patients With Early-Stage IA-IIA Cutaneous T-Cell Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT00961220·17 enrolled

O6-benzylguanine and Carmustine in Treating Patients With Stage IA-IIA Cutaneous T-cell Lymphoma

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT00003613·20 enrolled

Anaplastic Astrocytoma2 trials

Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma

Terminated·IIsarna Therapeutics GmbH·Phase 3·NCT00761280·27 enrolled

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Anaplastic Astrocytoma

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00003621·29 enrolled

Leukemia2 trials

Comparison of Two Combination Chemotherapy Regimens in Treating Adults With Previously Untreated Leukemia or Lymphoma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 3·NCT00002766·170 enrolled

Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Relapsed Acute Lymphocytic Leukemia

Completed·UUniversity of Nebraska·Phase 2·NCT00002638·30 enrolled

Brain Cancer2 trials

Chemotherapy and Vaccine Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Recurrent or Refractory Brain Cancer

Completed·BBarbara Ann Karmanos Cancer Institute·Phase 2·NCT00014573

Radiation Therapy in Treating Patients With Brain Cancer

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00002620·212 enrolled

Metastatic Melanoma2 trials

Dacarbazine and Carmustine in Metastatic Melanoma

Terminated·WWestern Regional Medical Center·Phase 2·NCT01692691·1 enrolled

O6-benzylguanine and Carmustine in Treating Patients With Unresectable Locally Recurrent or Metastatic Melanoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00005961·40 enrolled

Stem Cell Transplantation2 trials

S9901 Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Men With Stage III or Stage IV Hodgkin's Disease

Terminated·SSWOG Cancer Research Network·Phase 3·NCT00005090·11 enrolled

Combination Chemotherapy and Interferon Alfa With or Without Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Myeloma

Unknown status·MMedical Research Council·Phase 3·NCT00002599·750 enrolled

Autologous Stem Cell Transplantation2 trials

Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab in Autologous Stem Cell Transplantation

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00591630·30 enrolled

Phase II Study of V-BEAM Conditioning Regimen Prior to Second Autologous Stem Cell Transplantation

Terminated·WWashington University School of Medicine·Phase 2·NCT01653418·10 enrolled

Graft Versus Host Disease1 trial

Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant

Completed·BBarbara Ann Karmanos Cancer Institute·Phase 2·NCT00691015·48 enrolled

Central Nervous System Lymphoma1 trial

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Central Nervous System Lymphoma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00003632·30 enrolled

Relapse1 trial

BEAM vs. 90-Yttrium Ibritumomab Tiuxetan (Zevalin®)/BEAM With ASCT for Relapsed DLBCL

Terminated·—·Phase 3·NCT02366663·3 enrolled

Chronic Myelogenous Leukemia1 trial

Chemotherapy and Peripheral Stem Cell Transplantation Followed by Immunotherapy in Treating Patients With Chronic Myelogenous Leukemia

Completed·UUniversity of Maryland, Baltimore·Phase 2·NCT00003727·22 enrolled

Recurrent1 trial

Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects

Recruiting·VVBI Vaccines Inc.·Phase 1/2·NCT03382977·98 enrolled

Hodgkin's Disease1 trial

Gemcitabine and Hodgkin's Disease Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Hodgkin's Disease

Completed·SStanford University·Phase 2·NCT00388349·146 enrolled

Uveal Melanoma1 trial

Transarterial Chemoembolization for the Treatment of Uveal Melanoma With Liver Metastases

Active, not recruiting·TThomas Jefferson University·Phase 2·NCT04728633·28 enrolled

Refractory Solid Tumors1 trial

Targeting Pediatric Brain Tumors and Relapsed/Refractory Solid Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i)

Recruiting·WWashington University School of Medicine·Phase 1·NCT05521984·20 enrolled

Hematologic Malignancy1 trial

Terminated·—·Phase 2·NCT01500161·1 enrolled

Acute Myeloid Leukemia1 trial

Combination Chemotherapy With or Without G-CSF in Treating Older Patients With Acute Myeloid Leukemia

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00002719·500 enrolled

Colorectal Cancer1 trial

Monoclonal Antibody Therapy Plus Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT00003543·18 enrolled

Efficacy and Safety1 trial

Efficacy and Safety of Venetoclax Combined With BEAM Pretreatment in Autologous Transplantation for DLBCL

Unknown status·RRuijin Hospital·N/A·NCT05863845·52 enrolled

Myeloma1 trial

SWOG-9321 Melphalan, TBI, and Transplant vs Combo Chemo in Untreated Myeloma

Completed·SSWOG Cancer Research Network·Phase 3·NCT00002548·899 enrolled

Brain Neoplasm1 trial

Phase II Study of Carmustine, Streptozocin, and Mercaptopurine for Refractory or Recurrent Brain Neoplasms

Completed·EEmory University·Phase 2·NCT00004688·35 enrolled

Prophylaxis1 trial

Sirolimus & Mycophenolate Mofetil as GvHD Prophylaxis in Myeloablative, Matched Related Donor HCT

Terminated·SStanford University·Phase 2·NCT01220297·3 enrolled

Stage IV Ovarian Epithelial Cancer1 trial

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer

Completed·UUniversity of Maryland, Baltimore·Phase 2·NCT00003413·32 enrolled

Anaplastic Large Cell Lymphoma1 trial

Combination Chemotherapy Followed By Stem Cell Transplant in Treating Young Patients With Progressive or Relapsed Anaplastic Large Cell Lymphoma

Unknown status·EEuropean Inter-group Cooperation on Childhood and Adolescent Non Hodgkin Lymphoma·N/A·NCT00317408·96 enrolled

Stem Cell1 trial

hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM)

Recruiting·LLeland Metheny·Phase 2·NCT05052957·16 enrolled

Phase 21 trial

Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT

Terminated·SStanford University·Phase 2·NCT00482053·3 enrolled

Metastatic Prostate Cancer1 trial

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Prostate Cancer

Completed·UUniversity of Maryland, Baltimore·Phase 2·NCT00003400·45 enrolled

Metastatic Colorectal Cancer1 trial

Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer

Completed·—·Phase 2·NCT00005981·13 enrolled

Induction Therapy1 trial

Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)

Terminated·UUniversity of California, San Francisco·Phase 2·NCT00632827·21 enrolled

Central Nervous System Cancer1 trial

Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Patients With Central Nervous System Cancer

Completed·HHerbert Irving Comprehensive Cancer Center·Phase 2·NCT00007982·30 enrolled

Waldenstrom macroglobulinemia1 trial

S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia

Withdrawn·SSWOG Cancer Research Network·Phase 2·NCT00723658

HIV infection1 trial

HIV-Resistant Gene Modified Stem Cells and Chemotherapy in Treating Patients With Lymphoma With HIV Infection

Withdrawn·FFred Hutchinson Cancer Center·Phase 1·NCT02343666

Refractory1 trial

O6-benzylguanine and Carmustine in Treating Children With Refractory CNS Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00003765·36 enrolled

Patients With Solid Tumors1 trial

O(6)-Benzylguanine and Carmustine in Treating Patients With Solid Tumors

Completed·—·Phase 1·NCT00002604·28 enrolled

Primary Brain Tumor1 trial

Radiolabeled Monoclonal Antibody Therapy After Radiation Therapy in Treating Patients With Primary Brain Tumors

Completed·—·Phase 1·NCT00003484·21 enrolled

Autoimmune Disease1 trial

Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases

Active, not recruiting·FFred Hutchinson Cancer Center·Phase 2·NCT00716066·53 enrolled

Relapsed/Refractory1 trial

Acalabrutinib Plus RICE for Relapsed/Refractory DLBCL

Unknown status·SSwedish Medical Center·Phase 2·NCT03736616·47 enrolled

Immunodeficiency1 trial

Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant

Active, not recruiting·AAIDS Malignancy Consortium·Phase 1/2·NCT02797470·11 enrolled

Soft Tissue Sarcoma1 trial

O6-benzylguanine and Carmustine in Treating Patients With Recurrent, Metastatic, or Locally Advanced Soft Tissue Sarcoma

Completed·UUniversity of Chicago·Phase 2·NCT00005066·12 enrolled

Glioblastoma1 trial

A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma

Terminated·KKaryopharm Therapeutics Inc·Phase 1/2·NCT04421378·74 enrolled

T-cell non-Hodgkin lymphoma1 trial

Yttrium Y 90 Basiliximab and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Mature T-cell Non-Hodgkin Lymphoma

Completed·—·Phase 1·NCT02342782·20 enrolled

Melanoma1 trial

Combination Chemotherapy in Treating Patients With Stage III or Stage IV Melanoma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00003346·80 enrolled

Diffuse Large B-Cell Lymphoma Activated B-Cell Type1 trial

A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 3·NCT02443077·94 enrolled

Regulatory

FDA Approval Timeline[5]

Jan 1, 1982

BICNU

NDA NDA017422

Sep 23, 1996

GLIADEL

NDA NDA020637

May 16, 2022

CARMUSTINE

NDA NDA215000

Sources

References

[1]
ClinicalTrials.gov — 165 trial records for Carmustine. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — BiCNU drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Carmustine compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Carmustine. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA215000). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Melissa K Accordino company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Glutathione Reductase Inhibitor[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: MMelissa K Accordino

BiCNU

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2027

Q3 2027

Trials by Indication[1]

Lymphoma49 trials

Glioblastoma Multiforme10 trials

Multiple Myeloma10 trials

Malignant Glioma9 trials

Glioma7 trials

Mantle Cell Lymphoma5 trials

Diffuse Large B-Cell Lymphoma5 trials

Breast Cancer4 trials

Lymphoid Malignancies4 trials

Bone Marrow Transplantation4 trials

Stem Cell Transplant4 trials

Chronic Lymphocytic Leukemia4 trials

Cutaneous T-cell lymphoma2 trials

Anaplastic Astrocytoma2 trials

Leukemia2 trials

Brain Cancer2 trials

Metastatic Melanoma2 trials

Stem Cell Transplantation2 trials

Autologous Stem Cell Transplantation2 trials

Graft Versus Host Disease1 trial

Central Nervous System Lymphoma1 trial

Relapse1 trial

Chronic Myelogenous Leukemia1 trial

Recurrent1 trial

Hodgkin's Disease1 trial

Uveal Melanoma1 trial

Refractory Solid Tumors1 trial

Hematologic Malignancy1 trial

Acute Myeloid Leukemia1 trial

Colorectal Cancer1 trial

Efficacy and Safety1 trial

Myeloma1 trial

Brain Neoplasm1 trial

Prophylaxis1 trial

Stage IV Ovarian Epithelial Cancer1 trial

Anaplastic Large Cell Lymphoma1 trial

Stem Cell1 trial

Phase 21 trial

Metastatic Prostate Cancer1 trial

Metastatic Colorectal Cancer1 trial

Induction Therapy1 trial

Central Nervous System Cancer1 trial

Waldenstrom macroglobulinemia1 trial

HIV infection1 trial

Refractory1 trial

Patients With Solid Tumors1 trial

Primary Brain Tumor1 trial

Autoimmune Disease1 trial

Relapsed/Refractory1 trial

Immunodeficiency1 trial

Soft Tissue Sarcoma1 trial

Glioblastoma1 trial

T-cell non-Hodgkin lymphoma1 trial

Melanoma1 trial

Diffuse Large B-Cell Lymphoma Activated B-Cell Type1 trial

FDA Approval Timeline[5]

References

Drug Info

Quick Facts

Related News